The accelerating development of incretin-based therapies demands fresh thinking on incretin economics. Recent phase 3 evidence for mazdutide in Chinese adults and orforglipron added to insulin therapy offers health economics and market access leaders concrete signals about efficacy across populations, tolerability trade-offs, and the persistent challenge of weight regain. These findings compel senior decision-makers to reconsider how they construct value frameworks, shape pricing strategies, and manage system dynamics in an environment where chronic therapy has become the norm.

Understanding Biological Variation and Its Economic Weight

Obesity presents as a condition of considerable heterogeneity. Diagnosis reliant on body mass index fails to capture the complex interplay of genetic, physiological, psychological and environmental factors that drive individual response. Age, sex, ethnicity and concomitant medications further influence outcomes. Such ethnic heterogeneity carries direct consequences for health economics because populations differ not only in treatment response but also in the BMI threshold at which cardiometabolic outcomes deteriorate. China, with 402 million adults living with overweight or obesity in 2021, illustrates the scale of the challenge. Individuals of Chinese and South Asian ancestry accumulate greater visceral adipose tissue and develop complications at lower BMI levels than those of European ancestry. Against this background, new trial data assume strategic importance.

What the Latest Evidence Reveals

In the JAMA-published GLORY-2 trial, 9 mg weekly subcutaneous mazdutide delivered a placebo-subtracted weight reduction of 15.1% at 60 weeks among Chinese participants with overweight or obesity, 16% of whom had type 2 diabetes at baseline. The same agent produced a more modest 5% difference in those with diabetes, a pattern observed consistently across weight-loss interventions. Reductions in systolic blood pressure, triglycerides and non-high-density lipoprotein cholesterol accompanied the weight loss.

Separately, the ACHIEVE-5 multinational trial evaluated once-daily oral orforglipron at 3 mg, 12 mg and 36 mg added to titrated insulin glargine with or without metformin or SGLT2 inhibitors. All doses improved HbA1c by between 1.58% and 1.88% compared with 0.79% for placebo. Insulin dose increases stayed markedly lower in the orforglipron arms (30–33%) than with placebo (75%). Participants lost up to 5.4% of body weight despite insulin use, and clinically significant hypoglycaemia did not rise. The FDA approved orforglipron for weight management in April 2026 and has requested further data on gastric retention, major adverse cardiovascular events and liver safety.

Translating Findings into Health Economics and Market Access Strategy

These results carry immediate incretin economics implications. The stronger performance of mazdutide in a Chinese population at elevated cardiometabolic risk supports arguments for regionally differentiated value-based pricing. Demonstrating earlier onset of complications at lower BMI levels can improve cost-effectiveness estimates and justify faster reimbursement decisions in Asia. Meanwhile, orforglipron’s ability to deliver weight loss and superior glycaemic control alongside reduced insulin titration offers a compelling offset to the weight-gain liability typically associated with insulin therapy. Such insulin-sparing effects should feature prominently in budget impact models.

Yet the chronic nature of treatment remains the central economic tension. Most patients experience substantial weight regain after discontinuation — roughly 52–56% of lost weight within one year when lifestyle support continues, rising to 66% without it. This reality inflates long-term budget impact and challenges the sustainability of widespread adoption. Health economics teams must therefore build models that incorporate realistic persistence curves, rebound weight trajectories and downstream savings from improved cardiometabolic outcomes rather than relying solely on in-trial efficacy.

Actionable Recommendations for Senior Leaders

HEOR directors should revise economic models to capture ethnic heterogeneity explicitly, incorporating differential complication rates at lower BMI thresholds for Asian populations. Budget impact analyses must stress-test assumptions around weight regain and persistence, moving beyond optimistic trial-based projections. Pricing strategists ought to prepare tiered regional strategies that reflect local epidemiology and willingness-to-pay thresholds, using value-based pricing mechanisms where outcome uncertainty remains high.

Market access teams need to engage early with Asian health authorities to shape evidence requirements and reimbursement pathways. Policymakers should consider dedicated funding streams for chronic obesity management coupled with mandatory real-world evidence collection to track long-term system costs and clinical benefits. Health systems, meanwhile, must develop therapeutic sequencing guidance that balances efficacy, tolerability, route of administration and acquisition cost.

Manufacturers such as Eli Lilly and Novo Nordisk have already shaped much of the incretin landscape; those following should learn from their experience by embedding health economics endpoints in late-stage programmes and designing trials that address payer evidence gaps from the outset.

Final Strategic Considerations

The new data on mazdutide and orforglipron do not merely expand therapeutic choice. They illuminate the economic trade-offs inherent in treating a heterogeneous, chronic condition with expensive yet effective agents. By placing incretin economics at the heart of decision-making, leaders can move beyond volume-driven market access toward sustainable, equitable and clinically meaningful obesity care. Success will depend on sophisticated modelling, regionally sensitive pricing strategies and policies that acknowledge both the promise and the cost of long-term metabolic management.

This reflection draws on the editorial published in JAMA (https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.10443).